Post Herpetic Neuralgia Therapies Market Report Overview
Request a Free Sample to learn more about this report
The global post herpetic neuralgia therapies market size was USD 1586million in 2021 and is projected to reach USD 2084.2million by 2028, at a CAGR of 3.9% during the forecast period.
The growth of the post herpetic neuralgia therapy market is primarily fueled by the increasing aging population globally. With age, susceptibility to shingles and the subsequent development of post-herpetic neuralgia (PHN) rise significantly. This demographic shift correlates with a heightened demand for effective therapies targeting PHN. Additionally, an evolving public health consciousness, marked by increased awareness about shingles and advancements in diagnostic tools, is contributing to early detection and intervention. Together, these factors are driving the demand for post herpetic neuralgia therapies, making them integral in addressing the healthcare needs associated with this condition.
COVID-19 Impact: Demand Surged Due to Increased Incidence of Herpes Zoster (HZ)
The COVID-19 pandemic has been unprecedented and staggering, with the market experiencing higher-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden market growth reflected by the rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.
The global post herpetic neuralgia therapies market experienced a profound impact due to the COVID-19 pandemic. With the reported increased incidence of Herpes Zoster (HZ), studies have explored a potential connection between COVID-19 vaccines and the reactivation of the varicella-zoster virus, resulting in HZ and subsequently contributing to the prevalence of post-herpetic neuralgia (PHN). Additionally, the pandemic has elevated awareness surrounding pain management within the healthcare sector, potentially leading to heightened diagnoses and increased treatment for post herpetic neuralgia. The pandemic's focus on healthcare priorities has underscored the importance of addressing pain-related conditions and influencing trends in the post herpetic neuralgia therapies market.
"Exploring Targeted Nerve Blockade with Botulinum Toxin to Achieve Tailored Interventions"
In the landscape of post herpetic neuralgia therapies, a noteworthy trend involves the exploration of targeted nerve blockade using botulinum toxin injections. Emerging research delves into the potential of botulinum toxin to selectively target specific nerves implicated in the pain pathways associated with PHN. Early studies indicate promising outcomes, demonstrating a reduction in pain intensity and an improvement in overall quality of life for affected individuals. Ongoing trials further investigate the long-term efficacy and safety of this approach, marking a significant stride in the pursuit of more effective and tailored interventions for managing post-herpetic neuralgia.
Post Herpetic Neuralgia Therapies Market Segmentation
Request a Free Sample to learn more about this report
By Type Analysis
Based on type, the global market can be categorized into drugs, patches, and steroid injectables.
Drugs: Anticonvulsants and antidepressants, constituting the drugs segment, form the core of post herpetic neuralgia (PHN) treatment. While effectively modulating nerve signals and reducing pain perception, these drugs may induce side effects like drowsiness and dizziness.
Patches: Patches, exemplified by Lidocaine and capsaicin variants, deliver medication directly to the affected area, providing targeted pain relief with minimal systemic side effects. They offer temporary relief, improving the overall quality of life for individuals coping with PHN.
Steroid Injectables: Steroid injectables offer potent anti-inflammatory relief directly to the affected nerve, addressing severe PHN attacks in the short term. However, repeated use may pose risks of nerve damage, restricting their long-term viability in PHN management.
By Application Analysis
Based on application, the global market can be categorized into hospital pharmacies, online pharmacies, and retail pharmacies.
Hospital Pharmacies: Critical for inpatient care, hospital pharmacies ensure immediate access to post herpetic neuralgia therapies, supporting effective treatment within medical facilities.
Online Pharmacies: Online pharmacies provide a convenient digital avenue for individuals to access and obtain prescribed post-herpetic neuralgia therapies, offering remote convenience and streamlined delivery services.
Retail Pharmacies: Found in local communities, retail pharmacies serve as accessible points for individuals seeking post herpetic neuralgia therapies, contributing to widespread availability and convenience.
"Rising Aging Population Demographics to Fuel Market Growth"
The ongoing demographic shift towards an increasingly aged population is a pivotal factor propelling post herpetic neuralgia therapies market growth. As individuals progress into older age brackets, their susceptibility to shingles (herpes zoster) and its consequential complication, post-herpetic neuralgia (PHN), rises significantly. This demographic trend establishes a compelling correlation between age and the development of PHN, serving as a primary catalyst for the heightened demand for therapies targeting this condition.
"Enhanced PHN Awareness to Drive Market Demand"
A paradigm shift in public health consciousness is underway, particularly concerning shingles and its aftermath, post-herpetic neuralgia (PHN). The widespread dissemination of knowledge about the risks associated with shingles, coupled with advancements in diagnostic tools, is fostering an environment conducive to early detection and intervention. This heightened awareness plays a pivotal role in driving demand within the post-herpetic neuralgia therapies market.
"Limited Treatment Efficacy and Side Effects to Hinder Market Enhancement"
The post herpetic neuralgia therapies market faces challenges due to the limited efficacy and notable side effects associated with existing treatments. First-line medications such as gabapentin and pregabalin often provide only partial pain relief, accompanied by significant side effects including drowsiness, dizziness, and cognitive impairment. These adverse effects not only hinder patient adherence but also impact overall satisfaction with the treatment regimen. Furthermore, the absence of targeted therapies addressing the specific mechanisms of PHN pain creates a gap in pain management options, diminishing the market appeal of existing choices. This constraint highlights the critical need for more effective and tolerable therapeutic interventions to enhance patient outcomes in the post herpetic neuralgia therapies market.
Post Herpetic Neuralgia Therapies Market Regional Insights
Request a Free Sample to learn more about this report
"The market is primarily segregated into Europe, North America, Asia Pacific, Latin America, and the Middle East and Africa."
"North America to Lead Due to the Region’s Extensive Insurance Coverage for Pain Management"
North America currently holds the leading position in the post herpetic neuralgia therapies market share. This dominance is bolstered by factors like rising awareness of PHN, extensive insurance coverage for pain management, and a robust pipeline of novel therapies under development within the region. However, emerging economies with rapidly aging populations and increasing healthcare investments are poised to challenge this lead in the coming years.
Key Industry Players
"Key Players Focus on Partnerships to Gain a Competitive Advantage"
Prominent market players are making collaborative efforts by partnering with other companies to stay ahead of the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolios.
List of Market Players Profiled
Endo Pharmaceuticals (U.S.)
Acorda Therapeutics (U.S.)
Daiichi Sankyo (Japan)
Teikoku Pharma (Japan)
December 2020: A significant milestone was achieved in the post herpetic neuralgia therapies market with the development of Tanezumab, a monoclonal antibody jointly developed by Eli Lilly and Pfizer, leading global pharmaceutical companies. Tanezumab, designed to target nerve growth factor (NGF), a key protein in pain sensitization, demonstrated promising outcomes in a phase 3 trial for treating post-herpetic neuralgia (PHN). Administered through an injection every 8 weeks, Tanezumab effectively blocks the binding of NGF to its receptors, presenting a novel and potentially impactful advancement in alleviating pain associated with PHN.
The study encompasses a comprehensive SWOT analysis and provides insights into future developments within the market. It examines various factors that contribute to the growth of the market, exploring a wide range of market categories and potential applications that may impact its trajectory in the coming years. The analysis takes into account both current trends and historical turning points, providing a holistic understanding of the market's components and identifying potential areas for growth.
The research report delves into market segmentation, utilizing both qualitative and quantitative research methods to provide a thorough analysis. It also evaluates the impact of financial and strategic perspectives on the market. Furthermore, the report presents national and regional assessments, considering the dominant forces of supply and demand that influence market growth. The competitive landscape is meticulously detailed, including market shares of significant competitors. The report incorporates novel research methodologies and player strategies tailored for the anticipated timeframe. Overall, it offers valuable and comprehensive insights into the market dynamics in a formal and easily understandable manner.
Market Size Value In
US$ 1586 Million in 2021
Market Size Value By
US$ 2084.2 Million by 2028
CAGR of 3.9% from 2021 to 2028
Historical Data Available
Type and Application
Frequently Asked Questions
What value is the global post herpetic neuralgia therapies market expected to touch by 2028?
The global post herpetic neuralgia therapies market is expected to reach USD 2084.2 million by 2028.
What CAGR is the post herpetic neuralgia therapies market expected to exhibit by 2028?
The post herpetic neuralgia therapies market is expected to exhibit a CAGR of 3.9% by 2028.
What are the driving factors of the post herpetic neuralgia therapies market?
The driving factors include the rising aging population, leading to increased susceptibility to shingles and post-herpetic neuralgia, and enhanced awareness of PHN.
What are the key post herpetic neuralgia therapies market segments?
The key market segments include types such as drugs, patches, and steroid injectables, as well as applications including hospital pharmacies, online pharmacies, and retail pharmacies.